New cocktail of drugs aims to tackle multiple myeloma early
NCT ID NCT05695508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing several new drug combinations, including teclistamab, talquetamab, and JNJ-79635322, in 160 people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if these combinations are safe and more effective than current treatments at controlling the disease before and after transplant. Participants will receive different drug regimens to find the best approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teclistamab, talquetamab, JNJ-79635322, daratumumab, lenalidomide, bortezomib, and dexamethasone
What this could lead to
If successful, this could lead to more effective and safer treatment combinations for newly diagnosed multiple myeloma, potentially improving remission rates and reducing the need for intensive chemotherapy and stem cell transplant.
What could go wrong
This is an early-phase (Phase 2) trial with a small number of participants (160), so results may not apply to all patients. The drug combinations may cause significant side effects, and it's uncertain if they will outperform current standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asklepios Clinic Hamburg Altona
RECRUITINGHamburg, 22763, Germany
-
Charité University Medicin Berlin
RECRUITINGBerlin, 12203, Germany
-
Clinic Chemnitz gGmbH
RECRUITINGChemnitz, 09113, Germany
-
Hamburg University Clinic Eppendorf
RECRUITINGHamburg, 20246, Germany
-
Technical University Munich
RECRUITINGMunich, 81675, Germany
-
University Clinic Düsseldorf
RECRUITINGDüsseldorf, 40225, Germany
-
University Clinic Freiburg
RECRUITINGFreiburg im Breisgau, 79106, Germany
-
University Clinic Schleswig-Holstein Campus Kiel
RECRUITINGKiel, 24105, Germany
-
University Clinic Technical University Dresden
RECRUITINGDresden, 01307, Germany
-
University Hospital Heidelberg
RECRUITINGHeidelberg, 69120, Germany
Contact
-
University Würzburg
RECRUITINGWürzburg, Germany